Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 12/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113189 | 0.87 | F2 (0.57) | F2PRSS1 | |
| SCHEMBL7109688 | 0.80 | F2 (0.57) | F2PRSS1 | |
| SCHEMBL7109001 | 0.79 | F2 (0.49) | F2PRSS1 | |
| SCHEMBL3746447 | 0.78 | F2 (0.49) | F2PRSS1GLA | |
| SCHEMBL7108151 | 0.77 | F2 (0.45) | F2PRSS1P2RX7LMNAMEN1 | |
| SCHEMBL7107385 | 0.77 | F2 (0.57) | F2PRSS1 | |
| SCHEMBL3746460 | 0.76 | F2 (0.47) | F2PRSS1GLA | |
| SCHEMBL3732073 | 0.76 | F2 (0.44) | F2P2RX7LMNAALDH1A1L3MBTL1 | |
| SCHEMBL3732117 | 0.76 | F2 (0.40) | F2PRSS1LMNAGLAL3MBTL1 | |
| SCHEMBL7111308 | 0.74 | F2 (0.54) | F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158218-A1 | Thrombin inhibitors | NANTERMET PHILIPPE G (US) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158218-A1 | Thrombin inhibitors | F2, SERPINC1, TFPI | F2 1/4885PRSS1 74/4885P2RX7 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.